**FORM 7**

**January 2021 - MONTHLY PROGRESS REPORT**

| | |
|---|---|
| Name of Listed Issuer: | **Ortho Regenerative Technologies Inc. (the "Company" or the "Issuer")** |
| Trading Symbol: | **ORTH** |
| Number of Outstanding Listed Securities: | **34 567 600** |
| Date: | **February 4th, 2021** |

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   **The Company continued to implement operational initiatives to meet the following business objectives:**

   - **The ongoing execution of the FDA required documentation and manufacturing related activities for the filing of a US FDA Investigational New Drug (IND) to test its lead product Ortho-R for rotator cuff tear repair in human following the designation by the FDA Office for Combination Products that Ortho-R is a Drug/Biologic combination product.**

   - **The prosecution of its patent families, in prominent world markets.**

- **Awaiting DTC eligibility in the coming weeks for the Company's shares listed on the OTCQB market in the United States and trading under the symbol "ORTIF".**

2. Provide a general overview and discussion of the activities of management.

**During the period, Management's focus was to:**

**(i) Continue cGMP clinical batch manufacturing activities prior to filing a US FDA IND to test Ortho-R for rotator cuff tear repair in human;**

**(ii) Develop and finalize the Clinical study protocol and other IND filing requirements for ORTHO-R, our lead program for rotator cuff tear repair;**

**a. MCRA, the company's US based orthopaedic specialty clinical research organization ("CRO") selected to conduct its upcoming rotator cuff tear repair Ortho-R human trial, and the Ortho Team continued working together on regulatory and clinical planning activities, including the clinical protocol, identification of investigators and clinical testing sites, and more.**

**(iii) Execute any required research and development, regulatory, manufacturing, or operational activities required to support the above initiatives, either internally or through the company's partners and key suppliers;**

**(iv) Actively promote itself to strategic partners interested in our biopolymer technology and/or active programs; and**

**(v) Actively promote itself to potential institutional and retail investors as well as healthcare-life science investment bankers and analysts to facilitate raising the capital required to fund its operations and upcoming clinical programs.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Nothing applicable during the period.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Nothing applicable during the period.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**The Company entered into a global licensing agreement (the "Agreement") with Hanuman Pelican Inc. ("Hanuman") for the use of the Buoy Suspension Fractional System in combination with Ortho-R, Ortho RTI's lead Chitosan PRP hybrid drug/biologic implant combination product. The Agreement grants Ortho RTI an exclusive global license (excluding Japan) to use, manufacture, sublicense and sell the Buoy Suspension Fractional System in combination with Ortho-R in the following fields: 1) Tendons, 2) Ligaments, 3) Meniscus, 4) Cartilage, and 5) Wound Healing (non-exclusive). Hanuman will also supply its Buoy Suspension Fractional**

**System as the exclusive Platelet Concentration System to be used in Ortho RTI's clinical trial at each clinical site participating in the upcoming US ORTHO-R phase I / II clinical trial for rotator cuff tears repair. Ortho-RTI will pay royalties on net sales of the Buoy Suspension Fractional System portion of the combined Ortho-R package.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   **Nothing applicable during the period.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   **Nothing applicable during the period.**

8. Describe the acquisition of new customers or loss of customers.

   **Nothing applicable during the period.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks

   **Nothing applicable during the period.**

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

    **Nothing applicable during the period**

11. Report on any labour disputes and resolutions of those disputes if applicable.

    **Nothing applicable during the period.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    **Nothing applicable during the period.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

    **Nothing applicable during the period**

14. Provide details of any securities issued and options or warrants granted.

    **Exercise of Warrants**

    **114,000 warrants were exercised during the month of January for gross proceeds of $57,000. As a result, 114,000 Class "A" shares were issued.**

15. Provide details of any loans to or by Related Persons.

**Nothing applicable during the period.**

16. Provide details of any changes in directors, officers or committee members.

**Nothing applicable during the period**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The outbreak of a novel strain of the coronavirus, ("COVID-19"), has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown which may impact some of the operational initiatives we are currently pursuing in order to meet our business objectives. Those initiatives include planning activities for the filing of a US FDA IDE, completing the pre-clinical histology samples analysis final report, continuing cGMP manufacturing scale up activities, executing the ORTHO-R Clinical study plan for rotator cuff repair and our ability to timely secure access to supplies. As of today, we have been mildly impacted by the COVID-19 outbreak and we continue to interact with the scientific, medical and financial communities to mitigate as best as possible any impact that could affect negatively our timelines. Our employees, their families as well as our outsourced collaborators are the most important assets we have, and we are taking all actions to protect and accommodate them during these challenging times.**

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All the information in this Form 7 Monthly Progress Report is true.

Dated: February 4th, 2021

Ortho Regenerative Technologies Inc.
*/s/ Luc Mainville*

Senior VP & Chief Financial Officer
Official Capacity

| ***Issuer Details***<br>Name of Issuer<br>Ortho Regenerative Technologies Inc. | For Month End<br><br>January 2021 | Date of Report<br>YY/MM/D<br>2021/02/04 |
|---|---|---|
| Issuer Address<br>16667, Boul. Hymus, | | |
| City/Province/Postal Code<br>Kirkland, Quebec, H9H 4R9 | Issuer Fax No.<br>514.694.0443 | Issuer Telephone No.<br>514.694.0865 |
| Contact Name<br>Luc Mainville | Contact Position<br>Sr. VP & CFO | Contact Telephone No.<br>(514) 693-8854 |
| Contact Email Address<br>mainville@orthorti.com | Web Site Address<br>www.orthorti.com | |